By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


SAGE Therapeutics 

29 Newbury Street

Boston  Massachusetts  02116  U.S.A.
Phone: n/a Fax: n/a



Start Up

Company News
SAGE Therapeutics Receives Fast Track Designation For Lead Compound SAGE-547 To Treat Status Epilepticus 7/22/2014 6:49:33 AM
SAGE Therapeutics Announces Full Exercise Of Over-Allotment Option 7/21/2014 4:04:07 PM
SAGE Therapeutics Announces Pricing Of Initial Public Offering 7/18/2014 10:58:40 AM
Cambridge's SAGE Therapeutics Ups Proposed IPO Deal Size 7/17/2014 8:46:21 AM
Cambridge-Based SAGE Therapeutics Readies $69 Million IPO Pitch To Develop CNS Drugs 6/18/2014 6:59:12 AM
SAGE Therapeutics Appoints James M. Frates To The Company’s Board Of Directors 6/10/2014 6:48:07 AM
SAGE Therapeutics Presents Preliminary SAGE-547 Clinical Data At Epilepsy Pipeline Conference 6/5/2014 10:00:28 AM
Ligand Pharmaceuticals Inc. (LGND) Earns Milestone From SAGE Therapeutics For SAGE-547 5/12/2014 8:57:34 AM
SAGE Therapeutics Appoints Thomas D. Anderson As Chief Commercial Strategy Officer 5/5/2014 6:47:20 AM
SAGE Therapeutics Appoints Howard H. Pien To The Company’s Board Of Directors 4/1/2014 7:07:44 AM